Status:
RECRUITING
Comparison of 40% Glucose Solution and Autologous Blood Patch Pleurodesis for Postoperative Air Leak After Lung Resections
Lead Sponsor:
Wielkopolskie Centrum Pulmonologii i Torakochirurgii
Collaborating Sponsors:
Poznan University of Medical Sciences
Conditions:
Prolonged Air Leak
Persistent Air Leak
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Prolonged or persistent air leak (PAL) is one of the most common complications in patients after surgery on the lung parenchyma. Air leaks typically originate from alveolar-pleural fistulas, which can...
Detailed Description
Prolonged or persistent air leak (PAL) is one of the most common complications in patients after surgery on the lung parenchyma. Air leaks typically originate from alveolar-pleural fistulas, which can...
Eligibility Criteria
Inclusion
- Age: patients aged 18 years or older.
- Surgical Procedure: patients who underwent anatomical lung resections (segmentectomy, lobectomy, or bilobectomy) at the Department of Thoracic Surgery, Poznan University of Medical Sciences, between November 2023 and December 2024.
- Prolonged Air Leak Diagnosis: patients with diagnosed PAL after lung resection, as defined by air leakage persisting beyond 5 days post-surgery.
- Consent: patients who were willing to provide informed consent for participation in the study and for the intervention procedures (autologous blood pleurodesis or 40% glucose solution pleurodesis).
Exclusion
- Non-Anatomical Resections: Patients who underwent non-anatomical resections, such as pneumonectomy, lung transplantation, sleeve resections, or wedge resections.
- Patients from whom the required volume of peripheral blood (120 ml) could not be collected.
- Active Infection or Sepsis: Patients with ongoing infections or sepsis at the time of enrollment.
- Reoperation or Additional Interventions: patients who required immediate reoperation or other interventions that disturb the process of treating PAL.
- Mental Health or Cognitive Impairment: patients with significant cognitive impairments or mental health conditions that hinder the ability to provide informed consent or comply with study procedures.
- Patients who failed to perform three ABPP or 40% glucose injections (no consent, need for urgent surgery).
Key Trial Info
Start Date :
December 22 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2027
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06936969
Start Date
December 22 2023
End Date
May 1 2027
Last Update
April 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wielkopolskie Centrum Pulmonologii i Torakochirurgii
Poznan, Wielkopolska, Poland, 60-569